



Patent
Attorney Docket No. 028754-039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ross, Douglas D. et. al.

Application No.: 09/961,086

Filing Date: September 21, 2001

Title: Breast Cancer resistance Protein (BCRP) and the DNA which Encodes it

Group Art Unit: 1642

Examiner: Susan Ungar

Confirmation No.: 6592

FOURTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FOURTH Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: April 13, 2004

By


Jennifer A. Topmiller, Ph.D.
Registration No. 50,435


To assist the Examiner, the document is / documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date April 13, 2004

By:


Jennifer A. Topmiller, Ph.D.
Registration No. 50,435

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/961,086
Filing Date	September 21, 2001
First Named Inventor	Ross, Douglas D. et. al.
Examiner Name	Susan Ungar
Attorney Docket Number	028754-039

APR 13 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CHANG-JIE CHEN, ET AL., "Genomic Organization of the Human Multidrug Resistance (MDR1) Gene and Origin of P-glycoproteins", The Journal of Biological Chemistry, Vol. 265(1):506-514 (1999)
	A. AUSTIN DOYLE ET AL., "Characterization of a 95 Kilodalton Membrane Glycoprotein Associated with Multi-Drug Resistance", Int. J. Cancer: 62:593-598 (1995)
	L.A. DOYLE ET AL., "Expression of a 95 kDa Membrane Protein is Associated with Low Daunorubicin Accumulation in Leukaemic Blast Cells", Br. J. Cancer 1995 Jan.;71(1)52-8
	D.D.ROSS ET AL., "Expression of Multidrug Resistance-Associated Protein (MRP) mRNA in Blast Cells from Acute Myeloid Leukemia (AML) Patients", Leukemia (1996) 10, 48-55
	D.D.ROSS ET AL., "Susceptibility of Idarubicin, Daunorubicin, and Their C-13 Alcohol Metabolites to Transport-Mediated Multidrug Resistance", Biochemical Pharmacology, Vol. 50(10):1673-1683 (1995)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.